Blood, December 2014
Title: Immunotherapeutic Targeting of EphA3. Charmsaz S, Miller KJ, Day BW, El-Ajeh F., Paleth V., Bebbington CR, Scott AM, Lackmann M, Boyd A. Blood. 2014;124(21)
Growth Factors, December 2014
Title: A high affinity recombinant antibody to the human EphA3 receptor with enhanced ADCC activity. Tomasevic N, Luehrsen K, Baer M, Palath V,Martinez D, Williams J, Yi C, Sujatha-Bhaskar S, Lanke R, Leung J, Ching W, Lee A, Bai L, Yarranton G, Bebbington C. Growth Factors. 2014:Dec;32(6):223-235.
American Society of Hematology (“ASH”) Annual Meeting, December 2014
Title: KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, is Active and Well Tolerated in a Phase 1/2 Study of Advanced Hematologic Malignancies.
KaloBios ASH 2014 Poster Abstract
The Journal of Cancer Research, August 2014
Title: Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Vail ME, Murone C, Tan A, Hii Linda, Abebe D, Janes PW, Lee FT, Baer M, Palath V, Bebbington C, Yarranton G, Llerena C, Garic S, Abramson D, Cartwright G, Scott AM, and Lackmann. Cancer Res. August 2014;74:4470-4481.
American Society of Hematology (“ASH”) Annual Meeting, December 2013
Title: A Phase I Study of KB004, a Novel Non-fucosylated Humaneered® Antibody, Targeted Against the Receptor Tyrosine Kinase EphA3 in Advanced Hematologic Malignancies.
KaloBios ASH 2013 Poster Abstract
American Society of Hematology (“ASH”) Annual Meeting, December 2010
Title: A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples
KaloBios ASH 2010 Poster Abstract
American Society of Hematology (“ASH”) Annual Meeting, December 2009
Title: A Recombinant Human Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Shows Selective Cytotoxicity Against Myeloid Leukemia Cells and CD123-Positive Leukemic Stem Cells
KaloBios ASH 2009 Poster Abstract
Disclaimer: The information contained in the listed publications concerns biologics that are under pre-clinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.